Middle/high school students with asthma were found more likely to use 5 different tobacco products vs classmates without asthma.
AstraZeneca at ATS 2024: Look for Late-Breaking Data on Novel Therapeutics for COPD
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
Eternal Springs
Doctors, especially primary care doctors, love stories. We love hearing them from patients and telling them to one another. “Anecdotal learning” it’s called by some (somewhat derisively because it’s not science).
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improves Lung Function, Asthma Control: Daily Dose
Your daily dose of the clinical news you may have missed.